Testing effectiveness (Phase 2)Looking for participantsNCT07008638
What this trial is testing
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Who this might be right for
Acute Myeloid LeukemiaTP53
Masonic Cancer Center, University of Minnesota 32